Johnson & Johnson (JNJ)
| Market Cap | 386.61B |
| Revenue (ttm) | 78.71B |
| Net Income (ttm) | 38.02B |
| Shares Out | 2.41B |
| EPS (ttm) | 15.06 |
| PE Ratio | 10.67 |
| Forward PE | 15.01 |
| Dividend | $4.96 (3.09%) |
| Ex-Dividend Date | Aug 27, 2024 |
| Volume | 5,838,670 |
| Open | 159.75 |
| Previous Close | 159.64 |
| Day's Range | 159.47 - 161.58 |
| 52-Week Range | 143.13 - 175.97 |
| Beta | 0.52 |
| Analysts | Buy |
| Price Target | 172.23 (+7.22%) |
| Earnings Date | Jul 17, 2024 |
About JNJ
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lu... [Read more]
Financial Performance
In 2023, JNJ's revenue was $85.16 billion, an increase of 6.46% compared to the previous year's $79.99 billion. Earnings were $35.15 billion, an increase of 95.94%.
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for JNJ stock is "Buy." The 12-month stock price forecast is $172.23, which is an increase of 7.22% from the latest price.
News
Courts, Congress Likely to Stand in Way of J&J's Third Texas Two-Step Plan
PHILADELPHIA--(BUSINESS WIRE)--Lawyers on behalf of tens of thousands of ovarian cancer victims are calling on Johnson & Johnson (NYSE: JNJ) to end its “war of attrition against cancer victims.” “The ...
FINAL DEADLINE: Ovarian Cancer Victims Have Until 5pm ET Today to Vote on Approximately $8 Billion J&J Talc Compensation Plan
NEW YORK--(BUSINESS WIRE)--Today at 5pm ET is the final deadline for tens of thousands of ovarian cancer victims or their representatives to vote on the approximately $8 billion Johnson & Johnson (“J&...
Johnson & Johnson Receives Positive CHMP Opinion for Yuvanci® (Single Tablet Combination Therapy [STCT] of Macitentan and Tadalafil) for Treatment of Patients with Pulmonary Arterial Hypertension (PAH)
If approved, Yuvanci® would become the only single tablet combination for treatment for patients with PAH Johnson & Johnson's comprehensive PAH portfolio has the potential to cover all guideline-recom...
Johnson & Johnson to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4th, held at the New York Ma...
10 Dividend Stocks for Midyear
These dividend stocks to buy offer attractive yields at cheap prices.
Lawyers for Ovarian Cancer Victims Urge NO Vote on J&J's Latest Bankruptcy Plan
TRENTON, N.J.--(BUSINESS WIRE)--Thousands of individuals who are being told they may be eligible for quick and significant compensation from a proposed $6.5 billion bankruptcy settlement offered by Jo...
Should You Pick Johnson & Johnson Stock At $155 After Q2 Beat?
Johnson & Johnson (NYSE: JNJ) recently reported its Q2 results, with revenues aligning and earnings exceeding our estimates. The company reported revenue of $22.4 billion and adjusted earnings of $2.8...
Women Urge Support for $8 Billion J&J Talcum Powder Settlement as July 26th Deadline Approaches
NEW YORK--(BUSINESS WIRE)--Women diagnosed with ovarian cancer after using J&J's talcum powder products are urging others to vote in favor of the proposed settlement plan.
Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with treatment-resistant depression
Phase 4 SPRAVATO® monotherapy data shows rapid improvement in depressive symptoms at ~24 hours, sustained through at least 4 weeks Monotherapy submission builds on more than a decade of research, 31 c...
Johnson & Johnson Prioritizes Sustainable Growth in M&A Amid Sector Diversification, Says Analyst
Wednesday, Johnson & Johnson JNJ reported a second-quarter adjusted EPS of $2.82, up 10.2% Y/Y, beating the consensus of $2.70.
These Analysts Revise Their Forecasts On Johnson & Johnson After Q2 Results
Johnson & Johnson JNJ reported better-than-expected second-quarter earnings on Wednesday.
J&J MedTech Navigates Headwinds, Eyes Growth Surge in Second Half of 2024
Johnson & Johnson's (J&J) MedTech arm displayed resilience in its second quarter, navigating inflationary headwinds while prioritizing innovation. The unit, a key driver for J&J, remains committed to ...
Stock Market Today: Semis Get Slammed and Blue Chips Bounce
The potential for more curbs on tech sales to China set off a rotation into blue chips.
Stock Of The Day: Johnson & Johnson Hits Crucial Roadblock — Can It Break Through?
Investors loved the Johnson & Johnson JNJ earnings report. The stock is trading much higher, but it has stalled out around an important resistance level.
Johnson & Johnson CFO talks Q2 earnings, medtech business
Johnson & Johnson (JNJ) reported second-quarter earnings that beat estimates on both revenue and profit. The company posted revenue of $22.45 billion, surpassing the expected $22.34 billion, while adj...
JNJ Earnings: Broad Innovation & Top Line Performance
Johnson & Johnson (JNJ) looks undervalued with the market likely but not fully appreciating the broad innovation across the firm's pipeline, notes Morningstar's Damien Conover. He and Third Bridge's L...
Johnson & Johnson CFO on drug pricing
Johnson & Johnson executive vice president and CFO Joseph Wolk discusses high drug prices and breaks down the company's growth outlook.
Johnson & Johnson Posts Mixed Earnings, Shifts Full-Year Guidance
Johnson & Johnson (JNJ) reported mixed second-quarter results Wednesday, as one-time costs caused the company to miss profit estimates despite better-than-expected sales.
Nasdaq Dips 300 Points; Johnson & Johnson Earnings Top Estimates
U.S. stocks traded mostly lower this morning, with the Nasdaq Composite falling around 300 points on Wednesday.
Johnson & Johnson's Q2 Earnings: Revenue And Profit Beat On Strong Pharma Sales, Annual Profit Outlook Lowered On M&A Costs
On Wednesday, Johnson & Johnson JNJ reported a second-quarter adjusted EPS of $2.82, up 10.2% year-over-year, beating the consensus of $2.70.
J&J CFO Joseph Wolk on Q2 earnings beat: Very pleased with the performance overall
Johnson & Johnson executive vice president and CFO Joseph Wolk joins 'Squawk Box' to break down the company's quarterly earnings results, growth outlook, and more.
Johnson & Johnson beats on top and bottom lines in Q2
CNBC's Becky Quick reports on the company's quarterly earnings results.
Johnson & Johnson stock gets a lift from earnings beat, while outlook was mixed
Shares of Johnson & Johnson JNJ, +1.19% rose 1.1% in premarket trading Wednesday, after the drug maker beat second-quarter profit and sales expectations, while providing a mixed full-year outlook. Net...
Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2024
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2024 of $1.24 per share on the com...
J&J beats Wall Street estimates on strong drug sales
Johnson & Johnson beat estimates for second-quarter profit and revenue on Wednesday, driven by strong sales of its drugs, including cancer treatment Darzalex and blockbuster psoriasis drug Stelara.